Pathstone Holdings LLC Purchases 3,070 Shares of Insmed Incorporated (NASDAQ:INSM)

Pathstone Holdings LLC raised its holdings in shares of Insmed Incorporated (NASDAQ:INSM) by 9.5% during the third quarter, Holdings Channel reports. The fund owned 35,544 shares of the biopharmaceutical company’s stock after buying an additional 3,070 shares during the period. Pathstone Holdings LLC’s holdings in Insmed were worth $2,595,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new position in shares of Insmed during the 3rd quarter valued at $30,000. GAMMA Investing LLC boosted its position in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the period. First Horizon Advisors Inc. grew its stake in shares of Insmed by 83.4% during the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 287 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 627 shares during the period. Finally, EntryPoint Capital LLC bought a new stake in shares of Insmed in the 1st quarter valued at about $33,000.

Insider Transactions at Insmed

In other news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This represents a 11.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the transaction, the insider now owns 67,856 shares of the company’s stock, valued at approximately $5,045,093.60. The trade was a 29.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,882 shares of company stock valued at $5,765,446. Insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

INSM has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. TD Cowen boosted their price objective on shares of Insmed from $75.00 to $98.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Bank of America increased their target price on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Monday, September 9th. Finally, JPMorgan Chase & Co. increased their price objective on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Trading Up 1.3 %

NASDAQ:INSM opened at $74.09 on Tuesday. The firm has a market capitalization of $13.25 billion, a P/E ratio of -13.35 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The company’s 50-day simple moving average is $72.04 and its 200 day simple moving average is $66.60.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. During the same quarter in the prior year, the company posted ($1.10) earnings per share. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. As a group, analysts forecast that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.